| Oryzon

Skip to main content

English
Español

Company
- Overview
- Strategy
- Team
Epigenetics
- Epigenetics
- LSD1
Programs
Patients
- Clinical Trials
Investors
News & Events
- Press releases
- Events
Contact

Search

Breadcrumb

Home

11 September 2024

ORYZON receives “Intention to grant” communication for patent relating to the use of vafidemstat in Borderline Personality Disorder

9 September 2024

ORYZON announces first patient dosed in an Investigator-initiated Phase Ib study of iadademstat in first-line acute myeloid leukemia

3 September 2024

ORYZON continues to strengthen its patent portfolio for vafidemstat with additional “Decision to grant” communications

25-26 September 2024

Sachs Annual Biotech in Europe Forum 2024

Mövenpick Hotel Basel

Basel

Switzerland

21-24 September 2024

European College of Neuropsychopharmacology (ECNP) congress 2024

Allianz MiCo convention center, Milan

MI

Italy

2-3 September 2024

German Fall Conference 2024

Le Meridien Hotel

Frankfurt

Germany

29 August 2024

ORYZON to provide corporate progress updates at several events in September

31 July 2024

ORYZON reports financial results and corporate update for half-year ending June 30, 2024

8 July 2024

ORYZON receives “Decision to grant” for two important patents for vafidemstat in Japan

28 June 2024

ORYZON Announces Voting Results from its 2024 Annual General Meeting of Shareholders

Pagination

First page «
Previous page ‹
Page 7
Page 8
Page 9
Page 10
Current page 11
Page 12
Page 13
Page 14
Page 15
Next page ›
Last page »

Subscribe to

Company

Overview
Strategy
Team

Epigenetics

Epigenetics
LSD1

Programs

Pipeline
Iadademstat
Vafidemstat
Collaborations
Publications

Patients

Clinical Trials

Investors

Share Information
Financial Information
CNMV Filings
Analyst Coverage
Corporate Governance
Corporate Social Responsibility

News & Events

Press releases
Events

Contact

Contact
Email Alerts
Join us

© Oryzon Genomics, S.A. - All Rights Reserved

Legal
Privacy Policy
Cookie Policy
Ethics Channel